News Sentiment

CGEM sentiment intelligence

Cullinan Oncology LLC news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 56 Balanced news tone 50 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 18.13 Week of 10 Jul 2026
Weighted tone 56/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

87/100 classification confidence.

Company focus 42

directly relevant articles

Source quality 4

high-authority source matches

Trend context Trend active

+2.8% over one week, +32.3% over four weeks, trend active, and materially above fair value.

Latest direct headline Neutral

Cullinan CSO sells shares, exercises options | CGEM Insider Trading

Market Reaction

Balanced read

68/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 87/100 classification
One-week reaction 2.8% Price confirming higher
Trend fit Trend active 32.3% over four weeks
Fair value 44.4% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 16
Neutral 33
Negative 1

Relevance

Why the article matched

Direct first
Direct company coverage 42
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 14
Market source 6
Stock Traders Daily 4
Seeking Alpha 4
GlobeNewswire 4
Investing.com 3
TradingView 2
Finviz 2

Event Lens

What the news is about

Classified themes
Market update 36
Earnings 10
Guidance 2
Analyst action 1
Macro sensitivity 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-50 of 50
Stock Titan Direct company coverage

Cullinan Therapeutics (CGEM) posts early CLN-978 SLE and RA remission data

Cullinan Therapeutics reported initial Phase 1 data for CLN-978, a T cell engager, in treatment-refractory systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA), showing meaningful clinical and biologic signals. In SLE, 71% of patients achieved a significant reduction

Tone
Positive 67/100
Event
Market update
Published
08 Jun 2026 13:39
Source
Stock Titan
GlobeNewswire Direct company coverage

Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress

Cullinan Therapeutics presented initial Phase 1 clinical data for CLN-978, a CD19xCD3 T cell engager, at the EULAR 2026 Congress, demonstrating clinical benefit and remission in patients with systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The data showed deep,

Tone
Positive 75/100
Event
Market update
Published
06 Jun 2026 09:40
Source
GlobeNewswire
Stock Traders Daily Direct company coverage

Discipline and Rules-Based Execution in CGEM Response

This article analyzes Cullinan Oncology Inc. (NASDAQ: CGEM), identifying a near-term strong sentiment potentially shifting to neutral mid-term and positive long-term. It highlights an exceptional 63.5:1 risk-reward setup targeting a 16.9% gain with minimal risk and provides three

Tone
Positive 73/100
Event
Market update
Published
03 Jun 2026 07:40
Source
Stock Traders Daily
Finviz Direct company coverage

CGEM - Cullinan Therapeutics Inc Stock Price and Quote

Cullinan Therapeutics Inc. (CGEM) is a clinical-stage biopharmaceutical company focused on developing oncology and immuno-oncology therapies. The article provides detailed financial data, analyst ratings, and a comprehensive list of recent company news and insider transactions, i

Tone
Positive 67/100
Event
Analyst action
Published
26 May 2026 19:10
Source
Finviz